Novo Holdings A/S Portfolio Shifts: Significant New Positions & Sector Realignment
Novo Holdings A/S, a mid-cap focused investment trust, significantly reshaped its portfolio in Q2 2026 by adding new holdings like ALMS and DYN while reducing exposure to several existing stocks including AVBP.
As of June 30th, 2026, Novo Holdings A/S has strategically adjusted its investment portfolio. The fund's total value stands at $1.3 billion (1290475303), reflecting continued focus on mid-cap companies and specific sectors.
The most notable change involves three new significant positions acquired this quarter: ALUMIS INC (ALMS) with a 100% increase in shares, DYNE THERAPEUTICS INC (DYN) also showing a substantial 100% jump, and FLOOR & DECOR HLDGS INC (FND) which entered the portfolio entirely. These additions can be explored further at ALMS, DYN, and FND.
Concurrently, Novo Holdings A/S reduced its stake in several previously held companies. Notably, ARRIVENT BIOPHARMA INC (AVBP) saw a 22.77% decrease in holdings this quarter. Other significant reductions include PHARVARIS N V (PHVS) down by 20%, ENLIVEN THERAPEUTICS INC (ELVN) reduced by 21.88%, and CRINETICS PHARMACEUTICALS INC (CRNX) decreased by 14.84%. Detailed information on these holdings can be found at AVBP, PHVS, ELVN, and CRNX.
The fund also trimmed its positions in other Healthcare companies like CELLDEX THERAPEUTICS INC (NEW) (CLDX), down by 14.58%, and MIRUM PHARMACEUTICALS INC (MIRM), reduced by 15.09%. These changes are documented within the Novo Holdings A/S profile.
Despite these adjustments, Novo Holdings maintains a strong presence in certain sectors. The top holdings by weight remain heavily concentrated in Healthcare stocks like EDGEWISE THERAPEUTICS INC (EWTX) at 12.62%, ASML HOLDING N V (ASML) accounting for 10.97% of the portfolio, and BROOKFIELD CORP (BN) contributing 8.68%. Information on these top holdings is available at EWTX, ASML, and BN.
Overall, Novo Holdings A/S demonstrated active management in Q2 2026. The fund added three new major positions (ALMS, DYN, FND) and simultaneously reduced its stake in several other companies including AVBP, PHVS, ELVN, CRNX, CLDX, and MIRM.